Program
upadacitinib
Also written as “Upadacitinib”, “ABT-494” and “Upadacitinib 15 MG [Rinvoq]”.
Its studies are mostly in Dermatitis, Atopic · Arthritis, Rheumatoid · Crohn Disease · Colitis, Ulcerative · Alopecia Areata, led by 3 companies.
Drug pageUpadacitinib: every studyAll 98 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| AbbVieits history only | 6121 open or running | phase 4since Aug 18, 2022 | Dec 3, 2012 | Nov 2026phase 3 · NCT06389136 |
| CARE ARTHRITIS | 22 open or running | phase 4since Jun 6, 2024 | Jun 6, 2024 | May 2027phase 4 · NCT07018206 |
| Modern Biosciencesits history only | 11 open or running | phase 1since Apr 8, 2024 | Apr 8, 2024 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of CARE ARTHRITIS only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.
- Jun 9, 2016Named upadacitinibINNProposed as its International Nonproprietary Name in WHO's List 115 · before, ABT-494
- Jun 6, 2024First study: phase 4 study in Arthritis, PsoriaticFirst studyNCT06454188 · 100 planned · United States, Canada
- May 27, 2025Phase 4 study in Axial SpondyloarthritisNCT07018206 · 200 planned · United States
Ahead
- May 2027Primary completion: phase 4 study in Axial SpondyloarthritisNCT07018206
- Sep 2028Primary completion: phase 4 study in Arthritis, PsoriaticNCT06454188
TargetBeta
“Tyrosine-protein kinase TYK2 inhibitor; Tyrosine-protein kinase JAK3 inhibitor; Tyrosine-protein kinase JAK2 inhibitor; Tyrosine-protein kinase JAK1 inhibitor”ChEMBL 37, by rule
Other programs on the same 4 targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| ruxolitinibrule | Incyte | phase 4 | 95 |
| tofacitinibrule | Pfizer | phase 4 | 94 |
| filgotinib maleaterule | Eisai | phase 4 | 2 |
| filgotinibrule | Lakefront Biotherapeutics NV | phase 3 | 46 |
| delgocitinibrule | LEO Pharma | phase 3 | 21 |
Studies
All 2 CARE ARTHRITIS leads, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07018206Axial Spondyloarthritis · United States | 4 | Not yet recruiting | May 2027 | 200 |
| NCT06454188Arthritis, Psoriatic · United States, Canada | 4 | Recruiting | Sep 2028 | 100 |
How it is read
Names in the registry
- “Upadacitinib”, 54 entries
- “ABT-494”, 4 entries
- “Upadacitinib 15 MG [Rinvoq]”, 2 entries
- “Upadacitinib (ABT-494)”, 2 entries
- “Upadacitinib 15mg Dose”, 1 entry
Conditions, from the studies’ own filings
- Dermatitis, Atopic, 15 studies
- Arthritis, Rheumatoid, 14 studies
- Crohn Disease, 6 studies
- Colitis, Ulcerative, 4 studies
- Alopecia Areata, 3 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.